Alvotech and Advanz Pharma secure EC authorisation for treatment of immune-mediated diseases
News
Poolbeg granted European patent for POLB 001
New patent strengthens IP position for treatment of influenza side effects
TARA-002 shows strong early results in trial for paediatric lymphatic malformations
Protara’s phase 2 STARBORN-1 study reports high response rates and no serious adverse events
Libtayo approved in EU as first adjuvant immunotherapy for high-risk CSCC
New authorisation marks major milestone in earlier treatment of skin cancer
Cellbyte raises $2.75m to slash drug launch timelines with AI
Munich-based start-up backed by Frontline Ventures and Y Combinator eyes global expansion
GSK and Imperial launch £45m AI-powered AMR research drive
Six new Grand Challenges aim to tackle drug resistance and accelerate antibiotic discovery
Scottish Brain Sciences opens new Alzheimer’s research centre in Aberdeen
New ONE BioHub facility expands clinical trial access and strengthens Scotland’s brain health innovation
High dose nusinersen regimen receives positive CHMP opinion
New treatment option for spinal muscular atrophy moves closer to EU approval
Eisai shares long-term data on lecanemab at neurology congress
48-month analysis shows delayed progression and reduced risk in early Alzheimer’s patients
Mursla Bio partners with global pharma to advance precision medicine in liver disease
AI platform to support biomarker-guided therapy development in MASH
Evotec earns milestone payment as FDA clears IND for CELMoD candidate
US$5m payment from Bristol Myers Squibb marks progress in protein degradation partnership
Adocia unveils new long-acting peptide platform for diabetes and obesity
Patent filed for AdoXLong with promising monthly injection potential
Real-world data shows AUSTEDO improves life for patients with tardive dyskinesia
Findings highlight benefits in speech and daily activities alongside mental health stability
MSD’s oral cholesterol drug shows promise in late-stage trial
Enlicitide significantly reduces LDL-C in patients with high cardiovascular risk
MiNK Therapeutics unveils promising results for agenT-797 in resistant cancers
Allo-iNKT cell therapy shows durable survival and immune restoration in PD-1–refractory tumours
